GlaxoSmithKline PLC (NYSE:GSK) – Jefferies Group lowered their FY2018 earnings estimates for GlaxoSmithKline PLC in a report issued on Tuesday. Jefferies Group analyst J. Holford now forecasts that the pharmaceutical company will post earnings of $2.80 per share for the year, down from their previous estimate of $2.87. Jefferies Group also issued estimates for GlaxoSmithKline PLC’s FY2019 earnings at $2.93 EPS, FY2020 earnings at $3.22 EPS and FY2021 earnings at $3.48 EPS.

WARNING: “Jefferies Group Brokers Cut Earnings Estimates for GlaxoSmithKline PLC (GSK)” was first reported by Watch List News and is the property of of Watch List News. If you are accessing this piece on another site, it was stolen and reposted in violation of U.S. and international copyright and trademark law. The original version of this piece can be read at https://www.watchlistnews.com/jefferies-group-brokers-cut-earnings-estimates-for-glaxosmithkline-plc-gsk/1676239.html.

Several other equities research analysts have also recently commented on the company. J P Morgan Chase & Co restated a “neutral” rating on shares of GlaxoSmithKline PLC in a research note on Thursday, July 13th. Zacks Investment Research upgraded GlaxoSmithKline PLC from a “hold” rating to a “buy” rating and set a $47.00 price target for the company in a research note on Tuesday, July 18th. BidaskClub cut GlaxoSmithKline PLC from a “sell” rating to a “strong sell” rating in a research note on Monday, July 24th. Citigroup Inc. restated a “neutral” rating on shares of GlaxoSmithKline PLC in a research note on Thursday, July 27th. Finally, TheStreet cut GlaxoSmithKline PLC from a “b” rating to a “c+” rating in a research note on Wednesday, July 26th. Three investment analysts have rated the stock with a sell rating, nine have issued a hold rating and five have given a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus price target of $44.33.

Shares of GlaxoSmithKline PLC (NYSE:GSK) traded down $0.09 during midday trading on Wednesday, reaching $36.12. The company’s stock had a trading volume of 2,903,012 shares, compared to its average volume of 6,402,987. The company has a market cap of $88,412.41, a PE ratio of 12.75 and a beta of 1.00.

Hedge funds have recently made changes to their positions in the stock. Proficio Capital Partners LLC grew its holdings in GlaxoSmithKline PLC by 233.0% during the first quarter. Proficio Capital Partners LLC now owns 2,844 shares of the pharmaceutical company’s stock worth $122,000 after acquiring an additional 1,990 shares during the period. Westwood Holdings Group Inc. grew its holdings in GlaxoSmithKline PLC by 15.7% during the first quarter. Westwood Holdings Group Inc. now owns 2,950 shares of the pharmaceutical company’s stock worth $124,000 after acquiring an additional 400 shares during the period. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA grew its holdings in GlaxoSmithKline PLC by 1.9% during the second quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA now owns 3,374 shares of the pharmaceutical company’s stock worth $137,000 after acquiring an additional 64 shares during the period. FTB Advisors Inc. grew its holdings in GlaxoSmithKline PLC by 16.9% during the second quarter. FTB Advisors Inc. now owns 3,735 shares of the pharmaceutical company’s stock worth $146,000 after acquiring an additional 539 shares during the period. Finally, Advisory Services Network LLC grew its holdings in GlaxoSmithKline PLC by 24.2% during the second quarter. Advisory Services Network LLC now owns 4,047 shares of the pharmaceutical company’s stock worth $175,000 after acquiring an additional 788 shares during the period. 9.29% of the stock is currently owned by hedge funds and other institutional investors.

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, January 11th. Investors of record on Friday, November 10th will be issued a dividend of $0.5037 per share. This represents a $2.01 dividend on an annualized basis and a yield of 5.58%. The ex-dividend date is Thursday, November 9th. This is a positive change from GlaxoSmithKline PLC’s previous quarterly dividend of $0.49. GlaxoSmithKline PLC’s dividend payout ratio is currently 162.30%.

GlaxoSmithKline PLC Company Profile

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Earnings History and Estimates for GlaxoSmithKline PLC (NYSE:GSK)

Receive News & Ratings for GlaxoSmithKline PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.